Page 134 - 2020_07-Haematologica-web

I. Truxova et al.
AB
CD
E
P=0.037
P=0.027
P=0.039
P=0.035
P=0.05
Figure 5. Prognostic value of ecto-calreticulin and activating natural killer cell receptor NKG2D in acute myeloid leukemia patients. (A, B, C) Relapse-free sur- vival (RFS) of acute myeloid leukemia (AML) patients stratified in two groups based on median percentage of circulating ecto-CRT+ blasts (n=87) (A), on median mRNA levels of KLRK1 (n=37) (B) or the frequency of CD45+CD3–CD56+ natural killer (NK) cells staining positively for NKG2D (n=50) (C) analyzed upon complete remission. Survival curves were estimated by the Kaplan-Meier method and differences between groups were evaluated using log-rank test. Number of patients at risk is reported. (D, E) RFS of AML patients upon stratifi- cation based on median percentage of circulating ecto-CRT+ blasts along with median KLRK1 mRNA levels (D) or NKG2D+CD45+CD3-CD56+ NK cell frequency (E). Survival curves were estimated by the Kaplan-Meier method, and differ- ences between groups were evaluated using log-rank test. Number of patients at risk is reported. CRT: calreticulin.
1876
haematologica | 2020; 105(7)